These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2598178)

  • 1. THF-gamma 2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma.
    Ophir R; Pecht M; Halperin D; Rashid G; Burstein Y; Ben-Efraim S; Trainin N
    Cancer Immunol Immunother; 1989; 30(2):119-25. PubMed ID: 2598178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
    Ophir R; Pecht M; Burstein Y; Harshemesh H; Ben-Efraim S; Trainin N
    Int J Cancer; 1991 Apr; 48(1):96-100. PubMed ID: 2019463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocompetence status as related to growth progression of mouse MOPC-315 plasmacytoma.
    Rashid G; Ophir R; Pecht M; Ben-Efraim S
    In Vivo; 1989; 3(4):279-84. PubMed ID: 2535271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. THF-gamma 2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma.
    Ophir R; Pecht M; Relyveld EH; Burstein Y; Ben-Efraim S; Trainin N
    Int J Immunopharmacol; 1990; 12(7):751-4. PubMed ID: 2292455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
    Ben-Efraim S; Shoval S; Ophir R
    Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
    Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
    Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic thymic hormone, THF-gamma 2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan.
    Ophir R; Pecht M; Rashid G; Halperin D; Lourie S; Burstein Y; Ben-Efraim S; Trainin N
    Int J Cancer; 1990 Jun; 45(6):1190-4. PubMed ID: 2141006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.
    Rashid G; Ophir R; Pecht M; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):324-33. PubMed ID: 8941872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulation exerted by thymic humoral factor (THF-gamma 2), on T-cell subsets and IL-2 production of umbilical cord blood lymphocytes.
    Ben-Hur H; Pecht M; Netzer L; Borenstein R; Blickstein I; Burstein Y; Trainin N
    Immunopharmacol Immunotoxicol; 1990; 12(1):123-33. PubMed ID: 2112568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma.
    Ophir R; Moalem G; Pecht M; Shashoua M; Rashid G; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
    J Immunother; 1999 Mar; 22(2):103-13. PubMed ID: 10093035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the humoral immune response by particulate material extracted from spleen cell subpoulations of MOPC-315 tumor-bearing mice.
    Kleinman R
    Immunol Commun; 1979; 8(2):131-43. PubMed ID: 374242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory action of THF on T-cell reactivity to mitogens.
    Gabizon A; Trainin N
    Thymus; 1980 Jan; 1(4-5):225-39. PubMed ID: 6969474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.
    Shoval S; Ophir R; Ben-Efraim S
    Cancer Immunol Immunother; 1989; 29(4):279-87. PubMed ID: 2787695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of thymic hormone on the response of different lymphoid cell populations to T mitogens.
    Rotter V; Trainin N
    Isr J Med Sci; 1977 Apr; 13(4):363-70. PubMed ID: 301520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.